Navigation Links
Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
Date:12/3/2007

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced the appointment of Lesley A. Stolz, Ph.D., to the position of Vice President, Corporate and Business Development. Dr. Stolz will be responsible for overseeing the company's partnering and collaboration activities, reporting directly to Eric Bjerkholt, Senior Vice President, Corporate Development and Finance.

"We are pleased to welcome Lesley to the Sunesis team. Her proven track record and diverse experience in managing all aspects of partnering, in-licensing, intellectual property transfers and M&A activities will provide valuable insights to all of our strategic business development initiatives," said Daniel Swisher, Chief Executive Officer and President of Sunesis.

Dr. Stolz joins Sunesis with more than a decade of biotechnology industry experience. Most recently, she served as Senior Director, Business Development for Aerovance, Inc. where she led efforts to partner the company's Phase 2 asset for uncontrolled asthma. Dr. Stolz was Senior Director, Business Development for GPC Biotech AG of Germany from 2002 to 2006 where she co-led the acquisition of Axxima Pharmaceuticals. While there, she was also responsible for the discovery, evaluation and execution of GPC Biotech's in-licensing activities and helped to set business development and merger and acquisition strategies. From 2001 to 2002, Dr. Stolz served as Director, Business Development for Cell Genesys, Inc. with responsibility for identifying and negotiating partnerships for the compa
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... "The interface is the device," Nobel laureate Herbert ... to be found at the junctures where layers ... of nanotechnology, the interfaces between layers of metal ... such high-tech favorites as spintronics, high-temperature superconductors, ferroelectrics ...
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce ... , an e-Journal and producer of Food Labs ... year for the co-location of Food Labs Conference to be ... the registration fee to attend the two-day Food Lab Conference, ...
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... and SAN JOSE, California , ... biotechnology company developing antibody-drug conjugates for cancer, today announced the ... of Directors. Dr Reynolds has over 20 years, development experience ... Officer at Seattle Genetics. "I am delighted to ...
Breaking Biology Technology:A deeper look at interfaces 2Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3
... Sergio Lopez , 18, of Kyle, Texas , recently underwent a ... surgery to repair a broken bone in his arm that would not heal. ... device, such as a screw or plate. It,s this implantation that deterred Lopez ... , "I ...
... ,, HAIKOU CITY, China , ... CPHI ) ("China Pharma" or the "Company"), a leading,fully-integrated specialty pharmaceuticals company ... President, Ms. Zhilin Li , has,been invited to be a speaker ... Sciences Summit. , , , ...
... May 13 Repligen Corporation (Nasdaq: RGEN ... Drug Application (IND) with the Food and Drug Administration (FDA) ... deacetylase 3 (HDAC-3) inhibitor.  This is a double-blind, single ascending ... pharmacokinetic and safety profile of RG2833 in up to 40 ...
Cached Biology Technology:Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 2Texas Teen Opts for Stem Cell Therapy, Hopes of Enlisting in Military 3China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit 2China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit 3China Pharma Holdings, Inc. CEO to Speak at Brean Murray, Carret & Co. 2010 Life Sciences Summit 4Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 2Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 3Repligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich's Ataxia 4
(Date:4/23/2014)... -- Researchers have found evidence of an interaction ... increase aggressive behavior in children, especially in girls. ... children exposed to prenatal smoking will have behavioral ... said Brian Boutwell, Assistant Professor at Sam Houston ... author on the study. "One possible explanation ...
(Date:4/23/2014)... from using triclosan as an antimicrobial ingredient in soaps, ... scientists are reporting new evidence that appears to support ... Chemical Research in Toxicology , found that triclosan, ... the growth of human breast cancer cells in lab ... Choi and colleagues note that hormonal imbalances seem to ...
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... many neurodegenerative diseases the neurons of the brain are ... failed attempts and much scepticism this process was finally ... treatment in some patients with stroke. But very few ... In a new highly detailed study, researchers have ...
... microbiota in a new-born baby,s gut has been linked to ... week in PLOS Computational Biology . The findings ... the body,s microbial ecosystem - in an infant can influence ... gut of a new-born baby is quickly populated by a ...
... of large-bodied mammals inhabited the "mammoth steppe," a cold and ... northern Asia and across the Bering land bridge to the ... wolves and bears were able to maintain their ranges well ... new study led by researchers at the University of California, ...
Cached Biology News:Researchers discover a missing link in signals contributing to neurodegeneration 2Early infant growth rate linked to composition of gut microbiota 2Dietary flexibility may have helped some large predators survive after last ice age 2Dietary flexibility may have helped some large predators survive after last ice age 3
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
... version of Freezerworks Unlimited includes 2 clients and ... facilitates the sharing of freezers by multiple groups ... Network Client/Server version ... in monitor with 256 colors; OS 8.6 & ...
Polypropylene test tube racks, used in Thermo Forma's line of Test Tube Rack holders...
Mixing speed from 750-3200RPM, small vortexing orbit of1.0mm...
Biology Products: